There is a loss of time for patient care and a huge increase in time burden outside the visit for doctors and pharmacists. Another major insurance change coming next year will affect another large swath of Dushays patients: In January, BCBS Massachusetts will be excluding all GLP-1s from coverage for treatment of obesity, reserving coverage for these drugs only when indicated to treat type 2 diabetes
Not for diagnosis, therapeutic use or application in humans or animals
Bringing back comfort, sensation, and promoting nerve health is important
Transform your research with Retatrutide 10mg from ReVICO Labs
Favourable changes in cardiometabolic markers were also reported in the Phase 2 trial data, including reductions in: Systolic blood pressure Triglyceride levels Waist circumference (a proxy for visceral adiposity) However, these are surrogate markers and should not be interpreted as evidence of a reduction in major adverse cardiovascular events (MACE)
0.96%, in that order) [90]